Millipore and Proteome Sciences Announce Licensing Agreement
Proteome Sciences has established a strong portfolio of patent-protected blood biomarkers of Alzheimer’s disease working in collaboration with the Institute of Psychiatry (IoP) at King’s College London. A number of these biomarkers have been independently identified and their relationship to Alzheimer’s disease confirmed by researchers at GlaxoSmithKline.
Millipore will acquire the exclusive right to develop and sell Luminex bead-based panels for research related to the study of Alzheimer’s disease and other cognitive function disorders. Proteome Sciences retains all rights to clinical applications of these biomarkers. Financial terms of the license agreement were not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.